Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Crohn's disease: Adalimumab improves quality of life.

× No keyword cloud information.

10 in total

Review 1. Review article: economic issues in Crohn's disease--assessing the effects of new treatments on health-related quality of life.

Authors: B G Feagan
Journal: Aliment Pharmacol Ther Date: 1999-09 Impact factor: 8.171

2. The effects of infliximab maintenance therapy on health-related quality of life.

Authors: Brian G Feagan; Songkai Yan; Mohan Bala; Weihang Bao; Gary R Lichtenstein
Journal: Am J Gastroenterol Date: 2003-10 Impact factor: 10.864

Review 3. Inflammatory bowel disease.

Authors: Daniel K Podolsky
Journal: N Engl J Med Date: 2002-08-08 Impact factor: 91.245

Review 4. The quality of life in patients with Crohn's disease.

Authors: R D Cohen
Journal: Aliment Pharmacol Ther Date: 2002-09 Impact factor: 8.171

5. Quality of life in inflammatory bowel disease: psychometric evaluation of an IBDQ cross-culturally adapted version.

Authors: Ramiro Verissimo
Journal: J Gastrointestin Liver Dis Date: 2008-12 Impact factor: 2.008

Review 6. Current directions in IBD therapy: what goals are feasible with biological modifiers?

Authors: William J Sandborn
Journal: Gastroenterology Date: 2008-10-09 Impact factor: 22.682

7. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682

8. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

Authors: Edward V Loftus; Brian G Feagan; Jean-Frédéric Colombel; David T Rubin; Eric Q Wu; Andrew P Yu; Paul F Pollack; Jingdong Chao; Parvez Mulani
Journal: Am J Gastroenterol Date: 2008-10-03 Impact factor: 10.864

9. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.

Authors: Brian G Feagan; Remo Panaccione; William J Sandborn; Geert R D'Haens; Stefan Schreiber; Paul J Rutgeerts; Edward V Loftus; Kathleen G Lomax; Andrew P Yu; Eric Q Wu; Jingdong Chao; Parvez Mulani
Journal: Gastroenterology Date: 2008-08-03 Impact factor: 22.682

10. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.

Authors: Paul Rutgeerts; Stefan Schreiber; Brian Feagan; Dorothy L Keininger; Liz O'Neil; Richard N Fedorak
Journal: Int J Colorectal Dis Date: 2007-12-11 Impact factor: 2.571

10 in total